VPM

SHL Telemedicine's SmartHeart® Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials

Retrieved on: 
Tuesday, September 26, 2023
Health Technology, Telemedicine, Virtual Medicine, Data Management, Other Health, Technology, Apps, Applications, Managed Care, Biometrics, Medical Devices, Hospitals, Clinical Trials, Other Technology, Cardiology, Telecommunications, Biotechnology, Health, SHL, Telehealth, Mayo Clinic, VPM, ECG, Plaque, Vulnerable plaque, Patient, Imperial College London, Clinical professor, FDA, Pharmaceutical industry

Key highlights from the presentation of the initial results include:

Key Points: 
  • Key highlights from the presentation of the initial results include:
    A staggering decrease of- 27.5% in emergency room visits in the TELE-ACS trial1.
  • Erez Nachtomy, CEO of SHL Telemedicine, commented, "The initial results from the HELP-MI and TELE-ACS trials have surpassed our expectations.
  • We are extremely confident in the potential of our SmartHeart® technology, and these findings further validate its efficacy in post-MI patient care.
  • We are looking forward to the continued positive impact our technology will have on telemedicine and remote patient care."

SHL Announces Half-Year Results 2023 – Strategic Moves to Accelerate Growth

Retrieved on: 
Thursday, September 21, 2023
Hardware, IOT (Internet of Things), Health Technology, Telemedicine, Virtual Medicine, Data Management, Consumer Electronics, Other Health, Technology, Apps, Applications, Managed Care, Agritech, Other Technology, Telecommunications, Software, Health, SHL, Telehealth, Mayo Clinic, CET, Face, B2B, SIX Swiss Exchange, VPM, CVS, ECG, Docklands Strategic Development Zone, Cardiology, USD, Virtual visitation, Investment, Patient, CFO, Emergency department, Growth, Clinical professor, Hand, Imperial College London, Cryptocurrency, Fine chemical, Pharmaceutical industry, Bank, Marketing

SHL Telemedicine Ltd. (NASDAQ: SHLT; SIX Swiss Exchange: SHLTN) (“SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions, announced today its results for half-year 2023, emphasizing stable revenues and strategic growth initiatives.

Key Points: 
  • SHL Telemedicine Ltd. (NASDAQ: SHLT; SIX Swiss Exchange: SHLTN) (“SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions, announced today its results for half-year 2023, emphasizing stable revenues and strategic growth initiatives.
  • In H1 2023, SHL maintained stable revenues while making significant strategic advancements across all operations.
  • Preliminary results showcased at the Imperial Vulnerable Plaque and Patient Meeting 2023 (VPM) indicate significant benefits, reinforcing SHL's position in the field.
  • The Company will host a conference call for investors, journalists and analysts to discuss the Half-Year 2023 results today at 4 pm CET.

SHL Telemedicine's SmartHeart® Technology to Take Center Stage at Upcoming VPM 2023 Conference

Retrieved on: 
Monday, September 11, 2023
Finance, Hospitals, Clinical Trials, Health Technology, Telemedicine, Virtual Medicine, Professional Services, Cardiology, Biotechnology, Health, SHL, Telehealth, Mayo Clinic, Hospital, VPM, ECG, Multimedia, Major adverse cardiovascular events, MACE, Incidence, Plaque, Moyamoya disease, Gold, Patient, Mortality, Clinical professor, FDA, Imperial College London, Medical device

Both trials relate to the utilization of SHL's patented and FDA cleared SmartHeart® 12-lead ECG technology for remote monitoring of post-MI (heart attack) patients at home.

Key Points: 
  • Both trials relate to the utilization of SHL's patented and FDA cleared SmartHeart® 12-lead ECG technology for remote monitoring of post-MI (heart attack) patients at home.
  • "For years now, we have established and proven our technology’s value for Post MI (heart attack) patients, including significant reductions in mortality and readmission rates.
  • The conference will be held virtually on September 18 - 20th, 2023.
  • SHL Telemedicine is proud to be a SILVER level industry supporter of this conference.

Global Vehicle Parking Meter Market Size Anticipated to Reach USD 8.42 Billion By 2032, at a CAGR of 4.71%: Polaris Market Research

Retrieved on: 
Monday, June 19, 2023
Government, Hospital, VPM, Theft, LPR, Car, EHR, Safety, Movement, Warehouse

The vehicle parking meter market size is expanding due to the undemanding approach to services, and attendance of disbursement is another benefit of selecting parking meters.

Key Points: 
  • The vehicle parking meter market size is expanding due to the undemanding approach to services, and attendance of disbursement is another benefit of selecting parking meters.
  • Self-contained parking places: In some countries, parking management businesses generate modern propositions to reduce parking congestion and contribute to self-contained parking places.
  • Vehicle parking meter market demand is on the rise as it receives cash or tokens for vehicles to recompense for parking.
  • Vehicle parking meter market trends include the increasing demand for paying kiosks with technology's cost-effective maintenance prices.

EQS-News: VPM contributes to the successful licensure of the novel malaria vaccine R21/Matrix-MTM for first use in Ghana

Retrieved on: 
Wednesday, May 10, 2023
Vaccine, University of Oxford, DEK, Partnership, University, All, VPM, SII, Malaria, African, Licensure, Death, Serum Institute of India, Disease, Mortality, FDA, Pharmaceutical industry, Health

This synergistic collaboration facilitated the accelerated licensure process in Ghana and is a step forward on the path to ensuring vaccine equity in Africa.

Key Points: 
  • This synergistic collaboration facilitated the accelerated licensure process in Ghana and is a step forward on the path to ensuring vaccine equity in Africa.
  • Malaria is one of the leading causes of pediatric morbidity and mortality in sub-Saharan Africa.
  • R21/Matrix-MTM has emerged as the most effective vaccine against malaria ever produced and shall contribute to alleviating the burden of 600,000 deaths per year.
  • The licensure of the R21/Matrix-M Malaria Vaccine for use in Ghana and Nigeria is a significant milestone in our efforts to combat malaria around the world.

VPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG

Retrieved on: 
Wednesday, January 25, 2023
VPM, MTX, Infection, IND, BK, Pharmacokinetics, Therapy, Drug development, Trial of the century, Patient, Volunteering, Drug discovery, Viral load, Clinical trial, Knowledge, BKV, Fine chemical, Pharmaceutical industry

The project included a Phase I clinical trial with AntiBKV, an antibody targeting BK polyomavirus (BKV) infection in renal transplant patients.

Key Points: 
  • The project included a Phase I clinical trial with AntiBKV, an antibody targeting BK polyomavirus (BKV) infection in renal transplant patients.
  • VPM oversaw the clinical trial and performed translational project management, whereas the Australian cooperation partner and contract research organization (CRO) Accelagen managed the trial, yielding positive results, with all endpoints met.
  • In this phase I, single-blind, partially randomized, placebo-controlled clinical trial, 40 healthy adult volunteers were administered single and multiple ascending intravenous doses of AntiBKV (ClinicalTrials.gov: NCT05358106).
  • The broad expertise and commitment of VPM made the trial run smoothly, within budget and on time.

EQS-News: VPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG

Retrieved on: 
Thursday, February 2, 2023
IND, VPM, Infection, Therapy, Viral load, Trial of the century, Pharmacokinetics, Knowledge, Drug development, BK, BKV, Drug discovery, Patient, Clinical trial, Volunteering, MTX, Fine chemical, Pharmaceutical industry

The project included a Phase I clinical trial with AntiBKV, an antibody targeting BK polyomavirus (BKV) infection in renal transplant patients.

Key Points: 
  • The project included a Phase I clinical trial with AntiBKV, an antibody targeting BK polyomavirus (BKV) infection in renal transplant patients.
  • VPM oversaw the clinical trial and performed translational project management, whereas the Australian cooperation partner and contract research organization (CRO) Accelagen managed the trial, yielding positive results, with all endpoints met.
  • In this phase I, single-blind, partially randomized, placebo-controlled clinical trial, 40 healthy adult volunteers were administered single and multiple ascending intravenous doses of AntiBKV (ClinicalTrials.gov: NCT05358106).
  • The broad expertise and commitment of VPM made the trial run smoothly, within budget and on time.

Malwarebytes Expands Nebula Platform Across Threat Vectors

Retrieved on: 
Thursday, December 15, 2022
Cloud, Box, Trust, VPM, CSS, Security and Trust Services API for J2ME, G2 Crowd, Nebula, EDR, Software, Security, Microsoft OneDrive, Combine, Privacy, OS, MDR, USB, Organization, Hunting, EP, Artificial intelligence, CNET, Newsroom, Cloud storage, Infection, Machine learning, Video game console, Medical imaging, Computer data storage, Risk management, Malwarebytes

SANTA CLARA, Calif., Dec. 15, 2022 /PRNewswire/ -- Malwarebytes™, a global leader in real-time cyberprotection, continues to expand the Malwarebytes Nebula platform with additional threat prevention capabilities developed specifically for resource constrained organizations to reduce attack surfaces from a simple, easy-to-use cloud-based interface. Today, the company released Cloud Storage Scanning (CSS) to also protect business-critical assets stored in the cloud and prevent the introduction of malware and other threats into digital ecosystems.

Key Points: 
  • "In our evolution from endpoint product to a holistic protection platform, we're seeing strong adoption of our new threat prevention modules by customers that trust Malwarebytes to find and remediate more threats.
  • And this is just the beginning as we continue to address the latest threat vectors across the cloud and endpoints."
  • "Malwarebytes is consistently innovating and adding functionality to the platform," said Tony Archibald, Senior Director of IT Systems Living Water International.
  • With threat hunters and innovators across the world, the company is headquartered in California with offices in Europe and Asia.

TriHealth Partners with Andor Health for a Singular Approach to Virtual Care - Leading with Virtual Patient Monitoring

Retrieved on: 
Thursday, November 10, 2022
Review, Pharmacist, CPT, Counselor, Intelligence, Efficiency, Partnership, Communication, VPM, Technology, Diagnosis, TriHealth, Solution, AI, Nutritionist, Nursing, Patient, Health, Medical device

ThinkAndor VPM drives greater efficiency for the care team and improves patient responsiveness by collecting data from biometric devices and patient self-reported assessments.

Key Points: 
  • ThinkAndor VPM drives greater efficiency for the care team and improves patient responsiveness by collecting data from biometric devices and patient self-reported assessments.
  • "We started with Andor by building our Remote Patient Care service which helps us care for patients managing chronic conditions in-between office visits.
  • "As health systems continue to move to value-based care models , it is paramount to look at a unified platform approach for virtual care, including monitoring patients at home.
  • To learn how you can Achieve More with AI-Powered Virtual Care Experiences, visit Andor Health booth number 1527at HLTH in Las Vegas on Nov. 13-16.

How a Values-Based Approach Advances DEI

Retrieved on: 
Tuesday, June 7, 2022
People, Individual, Marvel Comics, Army, Research, Knowledge, Chapel Hill, MIT Sloan Management Review, Environment, VPM, University of North Carolina, Organization, University, Frustration, PNC Financial Services, United States Department of the Army, Department, UNC Kenan–Flagler Business School, Mayo Clinic, Attention, Workplace, DEI, Creative industries, Management, Google, Beach, The Walt Disney Company

CAMBRIDGE, Mass., June 7, 2022 /PRNewswire/ -- According to new research released today in MIT Sloan Management Review, achieving DEI isn't a linear process but rather a commitment to cultivating core values and turning guiding principles into organizational habits.

Key Points: 
  • "It is the best of times; it is the worst of times, when it comes to diversity, equity, and inclusion."
  • It forms a belief system that guides attitudes and motivates the actions of people within an organization.
  • "It is the best of times; it is the worst of times, when it comes to diversity, equity, and inclusion," states Anselm A.
  • Appreciationis recognizing the value DEI brings, being grateful for it, and relying on it to make an organization successful.